Shearman & Sterling is representing Boston Scientific in connection with the pending sale of BTG Specialty Pharmaceuticals to SERB SAS and Stark International Lux S.A.R.L., portfolio companies of private equity firm Charterhouse Capital Partners, for a cash purchase price of $800 million.

BTG Specialty Pharmaceuticals develops, manufactures and commercializes life-saving antidotes used in hospitals and emergency care settings.

The transaction is expected to close in the first half of 2021, subject to receipt of regulatory approvals and clearances and the satisfaction of other customary closing conditions.

The Shearman & Sterling team below also included associates Joon Lee, and Noni Nelson.

The Team